Eli Lilly's Promising Outlook in Healthcare Investment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: Fool
- Healthcare Spending Surge: According to the Peterson-KFF Health System Tracker, healthcare spending is projected to grow by 7.2% from 2023 to 2024, surpassing the average annual growth rate of 4.2% in the 2010s, indicating a robust expansion potential in the healthcare sector as the baby boomer population ages.
- Acquisition Strategy: Eli Lilly has announced its acquisition of Kelonia Therapeutics for approximately $7 billion, gaining access to the KLN-1010 CAR-T gene therapy currently in phase 1 trials, which enhances its competitive edge in cancer treatment and reflects the company's proactive approach to R&D.
- Strong Financial Performance: Lilly reported a 43% year-over-year revenue increase and a 51% rise in earnings per share (EPS) for the fourth quarter, showcasing its strong market performance, while its forward-looking price-to-earnings (P/E) ratio of 40 remains below the five-year average of 56, suggesting a reasonable valuation.
- R&D Investment Focus: Eli Lilly allocated 20.5% of its revenue to research and development in 2025, with about a quarter of its workforce dedicated to research, highlighting the company's commitment to future blockbuster drugs despite facing intense competition in the weight-loss drug market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 917.650
Low
950.00
Averages
1192
High
1500
Current: 917.650
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Increases Investment in Drug Development
- Increased R&D Investment: Eli Lilly announced a $7 billion investment to acquire privately held Kelonia Therapeutics and its KLN-1010 CAR-T gene therapy, indicating strong potential for growth in cancer treatment.
- Weight Loss Drug Pipeline: Eli Lilly leads in the weight loss drug sector with approved products on the market and more in development, which is expected to further drive future revenue growth for the company.
- Strong Financial Performance: The company reported a 43% year-over-year revenue increase and a 51% rise in earnings per share (EPS) for the fourth quarter, demonstrating its competitive edge and sustained profitability in the market.
- Reasonable Valuation: Although Eli Lilly's forward P/E ratio stands at 40, below its five-year average of 56, its strong financial performance suggests that investors should consider its long-term growth potential.
See More
Eli Lilly's Promising Outlook in Healthcare Investment
- Healthcare Spending Surge: According to the Peterson-KFF Health System Tracker, healthcare spending is projected to grow by 7.2% from 2023 to 2024, surpassing the average annual growth rate of 4.2% in the 2010s, indicating a robust expansion potential in the healthcare sector as the baby boomer population ages.
- Acquisition Strategy: Eli Lilly has announced its acquisition of Kelonia Therapeutics for approximately $7 billion, gaining access to the KLN-1010 CAR-T gene therapy currently in phase 1 trials, which enhances its competitive edge in cancer treatment and reflects the company's proactive approach to R&D.
- Strong Financial Performance: Lilly reported a 43% year-over-year revenue increase and a 51% rise in earnings per share (EPS) for the fourth quarter, showcasing its strong market performance, while its forward-looking price-to-earnings (P/E) ratio of 40 remains below the five-year average of 56, suggesting a reasonable valuation.
- R&D Investment Focus: Eli Lilly allocated 20.5% of its revenue to research and development in 2025, with about a quarter of its workforce dedicated to research, highlighting the company's commitment to future blockbuster drugs despite facing intense competition in the weight-loss drug market.
See More
Key Deals Reported Across Sectors This Week
- Merger Announcement: Helix Energy Solutions and Hornbeck Offshore Services have agreed to merge in an all-stock deal, creating a premier integrated offshore services company that aims to enhance market competitiveness and expand service offerings.
- Acquisition Agreement: Tesla disclosed in a regulatory filing its plan to acquire an unnamed AI hardware company for up to $2 billion in Tesla common stock and equity awards, indicating its ongoing expansion in the technology sector.
- Market Entry: KeyCorp is set to acquire UK-based Clearwater Corporate Finance, marking the diversified bank's entry into the Western European market, which is expected to enhance its international business capabilities.
- Significant Acquisition: Eli Lilly announced an agreement to acquire cancer drug developer Kelonia Therapeutics for up to $7 billion in cash, further solidifying its leadership position in the biopharmaceutical sector and expanding its product portfolio.
See More
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
Eli Lilly Increases Investment in Drug Development
- Increased R&D Investment: Eli Lilly announced a $7 billion investment to acquire privately held Kelonia Therapeutics and its KLN-1010 CAR-T gene therapy, indicating strong potential for growth in cancer treatment.
- Weight Loss Drug Pipeline: Eli Lilly leads in the weight loss drug sector with approved products on the market and more in development, which is expected to further drive future revenue growth for the company.
- Strong Financial Performance: The company reported a 43% year-over-year revenue increase and a 51% rise in earnings per share (EPS) for the fourth quarter, demonstrating its competitive edge and sustained profitability in the market.
- Reasonable Valuation: Although Eli Lilly's forward P/E ratio stands at 40, below its five-year average of 56, its strong financial performance suggests that investors should consider its long-term growth potential.
See More
Eli Lilly's Promising Outlook in Healthcare Investment
- Healthcare Spending Surge: According to the Peterson-KFF Health System Tracker, healthcare spending is projected to grow by 7.2% from 2023 to 2024, surpassing the average annual growth rate of 4.2% in the 2010s, indicating a robust expansion potential in the healthcare sector as the baby boomer population ages.
- Acquisition Strategy: Eli Lilly has announced its acquisition of Kelonia Therapeutics for approximately $7 billion, gaining access to the KLN-1010 CAR-T gene therapy currently in phase 1 trials, which enhances its competitive edge in cancer treatment and reflects the company's proactive approach to R&D.
- Strong Financial Performance: Lilly reported a 43% year-over-year revenue increase and a 51% rise in earnings per share (EPS) for the fourth quarter, showcasing its strong market performance, while its forward-looking price-to-earnings (P/E) ratio of 40 remains below the five-year average of 56, suggesting a reasonable valuation.
- R&D Investment Focus: Eli Lilly allocated 20.5% of its revenue to research and development in 2025, with about a quarter of its workforce dedicated to research, highlighting the company's commitment to future blockbuster drugs despite facing intense competition in the weight-loss drug market.
See More
Key Deals Reported Across Sectors This Week
- Merger Announcement: Helix Energy Solutions and Hornbeck Offshore Services have agreed to merge in an all-stock deal, creating a premier integrated offshore services company that aims to enhance market competitiveness and expand service offerings.
- Acquisition Agreement: Tesla disclosed in a regulatory filing its plan to acquire an unnamed AI hardware company for up to $2 billion in Tesla common stock and equity awards, indicating its ongoing expansion in the technology sector.
- Market Entry: KeyCorp is set to acquire UK-based Clearwater Corporate Finance, marking the diversified bank's entry into the Western European market, which is expected to enhance its international business capabilities.
- Significant Acquisition: Eli Lilly announced an agreement to acquire cancer drug developer Kelonia Therapeutics for up to $7 billion in cash, further solidifying its leadership position in the biopharmaceutical sector and expanding its product portfolio.
See More
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
